Accelerating Discovery and Characterization of Advanced Therapeutics with High-throughput Biomolecular Interaction Analysis
Date/time: Dec. 8, 2021 at 2pm ET
Using the label-free optical technique of Bio-Layer Interferometry (BLI), the Octet® platform provides real-time analysis of molecular interactions. It relies on the robust and easy-to-use Dip and Read™ format, which provides faster time to results relative to technologies like ELISA and SPR. It also operates in a fluidics-free format, thereby minimizing the complexity in analyte detection by fluidics-based technologies like SPR. The Octet® platform provides high-throughput analysis, with the option of analyzing up to 96 samples simultaneously, thereby increasing analytical productivity. It has high tolerance to a diverse array of sample types, making it compatible across the various steps from drug discovery to in-process testing during drug substance manufacturing. In addition, the samples analyzed on an Octet system can be reused for other analysis, minimizing depletion of resources, and maximizing process economy.
Key learnings:
How Octet® BLI works in therapeutic discovery and development, including common challenges and solutions
Adoption of the Octet® BLI in the development of advanced therapeutics such as Bispecific antibodies, Nanobodies and Antibody-drug conjugates
Benefits of using a real-time label free analytical tool such as the Octet® BLI relative to ELISA and SPR
Best practices and protocols to generate high-quality data quickly and easily using the Octet(r) BLI platform
Presenter:
Bob Dass, PhD
Senior Scientist, Sartorius